ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

elinzanetant

Also written as “Elinzanetant (BAY3427080)”, “GSK1144814” and “BAY3427080”.

Its studies are mostly in Hot Flashes · Schizophrenia, led by 2 companies.

Drug pageElinzanetant: every studyAll 25 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Aug 26, 202124 company-led studies, 2 open or runningNext primary completion: Jan 22, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bayer212 open or runningphase 3since Aug 26, 2021Aug 3, 2016Jan 22, 2027phase 1 · NCT07762287
GlaxoSmithKlineits history only30 open or runningphase 1since Mar 4, 2010Mar 4, 2010none ahead

Also a collaborator on its studies: Nerre Therapeutics and Quotient Sciences.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Bayer only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

Before these, 2 studies since Aug 3, 2016.

  1. Dec 9, 2019Named elinzanetantINNProposed as its International Nonproprietary Name in WHO's List 122 · before, GSK1144814, BAY3427080
  2. Nov 25, 2020Phase 1 study in HealthyNCT04654897 · 6 enrolled · United Kingdom
  3. Apr 7, 2021Phase 1 study in Multiple Endocrine Neoplasia Type 1NCT04845841 · 16 enrolled · Germany
  4. May 14, 20212 phase 1 studies in Multiple Endocrine Neoplasia Type 1NCT04889287, NCT04903821
  5. Jul 5, 2021Phase 1 study in Multiple Endocrine Neoplasia Type 1NCT04981431 · 62 enrolled · Japan
  6. Aug 26, 20212 phase 3 studies in Hot FlashesNCT05042362, NCT05030584
  7. Aug 26, 2021Phase 1 study in Multiple Endocrine Neoplasia Type 1NCT05028608 · 16 enrolled · Germany
  8. Sep 20, 20212 phase 1 studies in Multiple Endocrine Neoplasia Type 1NCT05061563, NCT05071729
  9. Oct 19, 2021Phase 3 study in Hot FlashesNCT05099159 · 400 enrolled · United States, Canada, Czechia and more
  10. Apr 25, 20222 phase 1 studies in Multiple Endocrine Neoplasia Type 1NCT05351892, NCT05381142
  11. Jul 21, 20222 phase 1 studies in Multiple Endocrine Neoplasia Type 1NCT05471817, NCT05481528
  12. Oct 17, 2022Phase 3 study in Hot FlashesNCT05587296 · 474 enrolled · Austria, Belgium, Canada and more
  13. Oct 27, 2023Phase 2 study in Sleep Disturbances Associated With MenopauseNCT06112756 · 110 enrolled · United States, Austria, Belgium and more
  14. Dec 21, 2023Phase 1 study in Multiple Endocrine Neoplasia Type 1NCT06219902 · 64 enrolled · Canada
  15. Jul 15, 2026Phase 1 study in Vasomotor Symptoms as a Sex Hormone-dependent Disorder in WomenNCT07762287 · 100 planned · Canada

Ahead

  1. Jan 22, 2027Primary completion: phase 1 study in Vasomotor Symptoms as a Sex Hormone-dependent Disorder in WomenNCT07762287

TargetBeta

“An orally bioavailable neurokinin/tachykinin 1 receptor (NK1-receptor; NK1R; NK-1R) and NK3 receptor (NK-3R; NK3R) antagonist, that may be used to treat vasomotor symptoms in menopausal woman”NCIt, by rule
“Neurokinin 1 receptor antagonist; Neurokinin 3 receptor antagonist”ChEMBL 37, by rule

Studies

All 21 Bayer leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07762287Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women · Canada1RecruitingJan 22, 2027100
NCT06219902Multiple Endocrine Neoplasia Type 1 · Canada1CompletedApr 15, 202464
NCT06112756Sleep Disturbances Associated With Menopause · United States, Austria, Belgium and more2CompletedAug 22, 2024110
NCT05587296Hot Flashes · Austria, Belgium, Canada and more3Active, not recruitingJan 29, 2024474
NCT05481528Multiple Endocrine Neoplasia Type 1 · Germany1CompletedFeb 7, 202351
NCT05471817Multiple Endocrine Neoplasia Type 1 · Germany1CompletedSep 20, 202220
NCT05381142Multiple Endocrine Neoplasia Type 1 · China1CompletedJul 11, 202216
NCT05351892Multiple Endocrine Neoplasia Type 1 · United States1CompletedJun 9, 202218
NCT05099159Hot Flashes · United States, Canada, Czechia and more3CompletedJun 13, 2023400
NCT05071729Multiple Endocrine Neoplasia Type 1 · United States1CompletedOct 19, 202231
NCT05061563Multiple Endocrine Neoplasia Type 1 · Netherlands1CompletedDec 9, 202114
NCT05030584Hot Flashes · United States, Belgium, Bulgaria and more3CompletedMar 29, 2023628
NCT05042362Hot Flashes · United States, Austria, Czechia and more3CompletedJul 25, 2023396
NCT05028608Multiple Endocrine Neoplasia Type 1 · Germany1CompletedOct 31, 202116
NCT04981431Multiple Endocrine Neoplasia Type 1 · Japan1CompletedMar 13, 202262
NCT04903821Multiple Endocrine Neoplasia Type 1 · Germany1CompletedMar 15, 202233
NCT04889287Multiple Endocrine Neoplasia Type 1 · Germany1CompletedJul 23, 202116
NCT04845841Multiple Endocrine Neoplasia Type 1 · Germany1CompletedJun 1, 202116
NCT04654897Healthy · United Kingdom1CompletedOct 29, 20206
NCT03596762Hot Flashes · United States, Canada, United Kingdom2CompletedNov 21, 2019199
NCT02865538Hot Flashes · United States2CompletedMar 28, 201776

How it is read

Names in the registry

  • “Elinzanetant (BAY3427080)”, 15 entries
  • “GSK1144814”, 7 entries
  • “BAY3427080”, 2 entries
  • “Elinzanetant (BAY 3427080) treatment A”, 1 entry
  • “Elinzanetant (BAY 3427080) treatment B”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.